Carboplatin and docetaxel in advanced non-small-cell lung cancer: results of a multicenter phase II study.
Cancer Chemother Pharmacol
; 53(5): 439-44, 2004 May.
Article
em En
| MEDLINE
| ID: mdl-15132135
ABSTRACT
BACKGROUND:
To evaluate the efficacy of carboplatin and docetaxel combination in patients with advanced non-small-cell lung cancer.METHODS:
In a phase II study, patients with inoperable stage IIIB or stage IV non-small-cell lung cancer (ECOG performance status of 0 or 1) were treated with the combination of carboplatin AUC 5 mg/ml.min and docetaxel 80 mg/m2 administered once every 3 weeks.RESULTS:
A total of 45 patients were accrued to the study. The median age was 62 years and adenocarcinoma was the most common histology. Patients received a median of four cycles of chemotherapy. The objective response rate was 29% with a median survival of 11.9 months among evaluable patients. The 1-year survival rate was 47%. Febrile neutropenia (17%) was the most common hematological toxicity associated with the regimen whereas grade 3 fatigue (4%) was the major nonhematological toxicity.CONCLUSIONS:
The combination of carboplatin plus docetaxel is well tolerated and is effective for the treatment of patients with previously untreated advanced or metastatic non-small-cell lung cancer.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Protocolos de Quimioterapia Combinada Antineoplásica
/
Carboplatina
/
Carcinoma Pulmonar de Células não Pequenas
/
Taxoides
/
Neoplasias Pulmonares
Tipo de estudo:
Clinical_trials
/
Prognostic_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2004
Tipo de documento:
Article